Innovation in nanomedicine represents a strong opportunity for human health and the growth of the pharmaceutical industry, and our society. NANOMIB is a Translational Medical Platform with the mission of exploring and developing nanodevices and algorithms for therapeutic, diagnostic and regenerative medicine, with clinical applications. The platform also takes advantage of the existing competences to exploit, using nanodevices, pharmaceutical, nutraceutical or diagnostic principles already developed by industrial, academic of research centers, bringing them to clinical application. The Platform actively pursues a well defined workflow for a direct or licensed exploitation of these results (see table above).
NANOMIB encompasses all the essential expertise and infrastructure needed to progress from preclinical studies to clinical trials. The collaborative synergy among research groups enables the seamless execution of every step, including nanostructure design, synthesis, physico-chemical and biological characterization, as well as in vitro and in vivo validation using animal disease models.
Furthermore, the affiliation to the Center of the Clinical area of the School of Medicine from UNIMIB at San Gerardo Hospital in Monza gives the concrete possibility of entering into clinical trials and transferring these technologies to the patients.